EUVIMEDEUVIMED entdecken
Systematische Übersicht

Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence

Rehab Emad Ashmawy iD, Olalekan John Okesanya iD, Bonaventure Michael Ukoaka iD, Faithful Miebaka Daniel iD, Sonsochukwu Godfrey Ezedigwe iD, Abdulmajeed Opeyemi Agboola iD, Mohamed Mustaf Ahmed iD, Jerico Bautista Ogaya iD, Blessing Olawunmi Amisu iD, Olaniyi Abideen Adigun iD, Olanegan Gloria Oluwakemi iD, Ayaat Mohamed Hamza iD und 3 weitere

Journal of Alzheimer’s Disease · 2025-06 · 105 (3) · 714-728

DOI: 10.1177/13872877251331640 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Alzheimer’s Disease, online erschienen am 15.04.2025. Verfasst von Rehab Emad Ashmawy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Helwan University, Cairo, Egypt. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment. Lecanemab has shown safety and efficacy in clinical trials.

Objective

This review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD.

Methods

A systematic search was conducted using the Scopus database and ClinicalTrials.gov. Studies from 2014 to 2024 on lecanemab's safety, efficacy, and clinical outcomes for AD were included. Data extraction involved two independent reviewers, with synthesis using qualitative methodology.

Results

Findings from 13 studies and 13 ongoing clinical trials were reported, showing that lecanemab substantially reduces amyloid plaque load in the brains of AD patients. The therapeutic regimens vary across reported studies and trials, ranging from 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, and 10 mg/kg intravenously biweekly. The Clarity AD phase 3 trial, the AHEAD study, and the DIAN-TU-001 trials have reported positive study outcomes with robust efficacy and safety outcomes with minimal side effects. Completed and ongoing trials report on the onset of amyloid-related imaging abnormalities (ARIA) and the continuation of care status following the onset of ARIA in these patients. The common infusion-related reactions were observed in 26.4% of the lecanemab group compared to 7% in the placebo group.

Conclusions

The management of AD has evolved over the years with the introduction of novel therapeutic agents like lecanemab. While its safety profile is generally favorable, careful monitoring is essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedHumansTreatment OutcomeClinical Trials as TopicPlaque, Amyloid

Stichwörter der Autor:innen

Alzheimer's diseaseBAN2401amyloid-betalecanemab

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Faculty of Medicine, Helwan University, Cairo, Egypt.
  • Department of Medical Laboratory Science, Neuropsychiatric Hospital, Abeokuta, Nigeria.
  • Faculty of Medicine, Department of Public Health and Maritime Transport, University of Thessaly, Volos, Greece.
  • Community and Clinical Research Division, First On-Call Initiative, Port Harcourt, Nigeria.
  • Department of Pharmacy, University College Hospital, Ibadan, Nigeria.
  • Department of Public Health, Al-Hikmah University, Ilorin, Nigeria.

ORCID-Profile: Rehab Emad Ashmawy, Olalekan John Okesanya, Bonaventure Michael Ukoaka, Faithful Miebaka Daniel, Sonsochukwu Godfrey Ezedigwe, Abdulmajeed Opeyemi Agboola, Mohamed Mustaf Ahmed, Jerico Bautista Ogaya, Blessing Olawunmi Amisu, Olaniyi Abideen Adigun, Olanegan Gloria Oluwakemi, Ayaat Mohamed Hamza, Marina Ramzy Mourid, Mbn Kouwenhoven, Don Eliseo Lucero-Prisno

Zitieren

APA

Ashmawy, R. E., Okesanya, O. J., Ukoaka, B. M., Daniel, F. M., Ezedigwe, S. G., Agboola, A. O., Ahmed, M. M., Ogaya, J. B., Amisu, B. O., Adigun, O. A., Oluwakemi, O. G., Hamza, A. M., Mourid, M. R., Kouwenhoven, M., & Lucero-Prisno, D. E. (2025). Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence. Journal of Alzheimer’s Disease, 105(3), 714-728. https://doi.org/10.1177/13872877251331640

Vancouver

Ashmawy RE, Okesanya OJ, Ukoaka BM, Daniel FM, Ezedigwe SG, Agboola AO, et al. Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence. Journal of Alzheimer’s Disease. 2025;105(3):714-728. doi:10.1177/13872877251331640

BibTeX
@article{Ashmawy2025,
  author = {Ashmawy, Rehab Emad and Okesanya, Olalekan John and Ukoaka, Bonaventure Michael and Daniel, Faithful Miebaka and Ezedigwe, Sonsochukwu Godfrey and Agboola, Abdulmajeed Opeyemi and Ahmed, Mohamed Mustaf and Ogaya, Jerico Bautista and Amisu, Blessing Olawunmi and Adigun, Olaniyi Abideen and Oluwakemi, Olanegan Gloria and Hamza, Ayaat Mohamed and Mourid, Marina Ramzy and Kouwenhoven, Mbn and Lucero-Prisno, Don Eliseo},
  title = {Exploring the efficacy and safety of lecanemab in the management of early Alzheimer’s disease: A systematic review of clinical evidence},
  journal = {Journal of Alzheimer’s Disease},
  year = {2025},
  volume = {105},
  number = {3},
  pages = {714--728},
  doi = {10.1177/13872877251331640}
}
Kostenlos starten →